Common questions and answers about Canadian Pharmacies.

Canadian Pharmacy Finds Genes Irrelevant In Breast Cancer Risk

Saturday 5 November 2011 - Filed under Canadian Pharmacy

Risk of breast cancer in women cannot be determined by genetic factors. In other words, if a relative has breast cancer, it does not mean other women in the family will also get the same. Our Canadian pharmacy elaborates on findings from a study published in the Journal of Clinical Oncology. International researchers observed mothers, daughters, and sisters in families with previous history of genetic mutations were not at risk.

Familial breast cancer risk is higher in women having BRCA1 and BRCA2 mutations. Previous studies have already indicated a tenfold higher risk factor in women with genetic mutations as compared to normal women. Genes are sometimes altered in the general population such as the ataxia telangiectasia (AT) thereby increasing the risk of ATM in the community.

Earlier, epidemiological studies were based on findings related to ATM heterozygosity or formation of different cells as occurring in breast cancer. Families with AT heterozygote women had increased risk of the disease and accounted for 1% of the general population. Increased risk of breast cancer should also reflect on normal women born to families with high risk; however, this was not the case.

Researchers from the School of Population Health based at the University of Melbourne revealed women had nothing to fear in terms of genetic factors. In the year 2007, researchers had indicated a five-fold higher risk, which was negated in the current study. AT patients are extremely sensitive to ionizing radiation. Post-menopausal women often buy Arimidex from our Canadian pharmacy for the treatment of breast cancer.

Also, tissue reaction was found to be extremely volatile or late after undergoing radiotherapy which led to the belief that AT heterozygosity was responsible for acute radio-sensitivity response and in the development of breast cancer. Though less heterozygosity around the ATM gene was observed in 40% of sporadic breast tumors, ATM genes were not involved and did not bring about the effect.

The current study was based on analysis of genetic mutations in 3,000 families having cases of breast cancer. It involved the study of close relatives like mothers, daughters, and sisters of patients suffering from breast cancer who could also be carriers of BRCA1 and BRCA2 mutations.

Protein truncation test often fails to identify mutations in laboratories in combination with the size of ATM genes. In other words mutation profiles in AT patients may not be similar when analyzed in connection with other diseases. Women should not be unnecessarily perturbed even if they have relatives in the family with high breast cancer risk. Excess screening to eliminate risk is not necessary. Non-carriers of genetic mutations are not at risk as proved by one of the largest studies conducted on women born in family-specific breast cancer mutations.

Our Canadian pharmacy agrees with researchers that if rare sequence variants known as polymorphisms are consistently found inside the ATM gene, more breast cancer patients can be assessed to find out their connection to developing cancerous growth and hypersensitivity to chemotherapy. In the meantime, women can lead an active life without worry of developing cancer, even if other members of their family have higher risk or have developed breast cancer.

2011-11-05  »  admin

Share your thoughts

Re: Canadian Pharmacy Finds Genes Irrelevant In Breast Cancer Risk

Sign in